POLICY DEBATES DURING THE PANDEMIC
While cell and gene therapies are constantly evolving and offer a lot of promise for rare and chronic conditions, they are also surrounded by a range of scientific, logistic and regulatory challenges. There is a clear need for decision-makers and experts to come together to define a sustainable way forward in ensuring safe and affordable access to novel treatments in this space. During this webinar our multi-stakeholder panel discussed transformative therapies and explored their impact on our health and on the systems that deliver them.
Bertalan Mesko
Director, The Medical Futurist Institute
Cristian Silviu Bușoi
MEP, European Parliament
Andrzej Rys
Director for Health Systems,DG SANTE, European Commission
Avril Daly
Vice-President, EURORDIS
Diane Kleinermans
President of the Commission of Drugs Reimbursement, Belgian National Institute for Health and Disability Insurance
Ilona G. Reischl
Quality Assessor - Biologics, Austrian Medicines and Medical Devices Agency (AGES/MEA)
Paige Bischoff
Senior Vice President, Global Public Affairs, Alliance for Regenerative Medicine (ARM)
Dan Hart
Honorary Consultant Haematologist, The Royal London Hospital Haemophilia Centre
Moderation: Vivienne Parry
Science journalist and writer, Head of Engagement, Genomics England